Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_227_библиотеки_им_акад_М_И_Перельмана
.pdf
121
72. Colonic motility abnormality in patients with irritable bowel syndrome
exhibiting abdominal pain and diarrhea / W. Y. Chey, H. O. Jin, M. H. Lee [et al.] // Am
J Gastroenterol. – 2001. Vol. 96, N 5. – P. 1499–1506.
73. Colonic mucosal immune activity in irritable bowel syndrome: comparison
with healthy controls and patients with ulcerative colitis/ J. Y. Ahn, K. H. Lee, C. H. [et
al.] // Choi Dig Dis Sci. – 2014. – Vol. 59, N 5. – P. 1001‒1011.
74. Comorbid clinical conditions in chronic fatigue: a co‒twin control study /
L. A. Aaron, R. Herrell, S. Ashton [et al.] // J Gen Intern Med. – 2001. – Vol. 16, N 1. –
P. 24-31.
75. Comorbidity in irritable bowel syndrome. / W. E .Whitehead, O. S.
Palsson, R. R. Levy [et al.] // Am. J. Gastroenterol. – 2007. – Vol. 102, N 12. – P.
2767–2776.
76. Comparison of bismuth citrate and 5‒aminosalicylic acid enemas in distal
ulcerative colitis: a controlled trial / R. D. Pullan, S. Ganesh, V. Mani [et al.] // Gut. –
1993. – № 34. – Р. 676–679.
77. Confocal endomicroscopy shows food‒associated changes in the intestinal
mucosa of patients with irritable bowel syndrome / A. Fritscher-Ravens, D. Schuppan,
M. Ellrichmann [et al.] // Gastroenterology. – 2014. – Vol. 147, N 5. – P. 1012–1020.
78. Confocal laser endomicroscopy detects colonic inflammation in patients
with irritable bowel syndrome: a prospective study / C. Robles‒Medranda, R. Oleas, M.
Valero [et al.] // Endosc Int Open. – 2020. – Vol. 8, N 4. – P. 550‒557.
79. Crowell, M. D. Role of serotonin in the pathophysiology of the irritable
bowel syndrome / M. D. Crowell // British Journal of Pharmacology. – 2004. – Vol.
141, N 8. – P. 1285–1293.
80. Cytokine imbalance in irritable bowel syndrome: a systematic review and
meta‒analysis / M. Bashashati, N. Rezaei, A. N. Shafieyoun [et al.] //
Neurogastroenterol Motil. – 2014. – Vol. 26, N 7. – P. 1036–1048.
81. Cytokines and irritable bowel syndrome: where do we stand / M.
Bashashati, N. C. Rezaei, N. Andrews [et al.] // Cytokine. – 2011. – Vol. 57, N 2. – P.
201–209.
https://t.me/med1917
122
82. Decreased expression of serotonin in the jejunum and increased numbers of
mast cells in the terminal ileum in patients with irritable bowel syndrome / S. H. Wang,
L. Dong, J. Y. Luo [et al.] // World J Gastroenterol. – 2007. – Vol. 13, N 45. – P. 6041‒
6047.
83. Depressive symptoms in patients with irritable bowel syndrome: a meta‒
analysis of comparative studies / Q. E. Zhang, F. Wang, W. Zheng [et al.] // Qin G Int J
Biol Sci. – 2018. – Vol. 14, N 11. – P. 1504‒1512.
84. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with
structural abnormalities in the jejunal epithelial barrier / C. Martínez, B. Lobo, M.
Pigrau [et al.] // Gut. – 2013. – Vol. 62, N 8. – P 1160-1168.
85. Disruption of the pro‒inflammatory, anti‒inflammatory cytokines and
tight junction proteins expression, associated with changes of the composition of the gut
microbiota in patients with irritable bowel syndrome / V. Ivashkin, Y. Poluektov, E.
Kogan [et al.] // PLoS One. – 2021. – Vol. 16, N 6. – DOI:
10.1371/journal.pone.0252930.
86. Economic burden of irritable bowel syndrome with constipation: a
retrospective analysis of health care costs in a commercially insured population / J. A.
Doshi, Q. Cai, J. L. Buono [et al.] // J Manag Care Spec Pharm. – 2014. – Vol. 20, N 4.
– P. 382‒90.
87. Economic burden of moderate to severe irritable bowel syndrome with
constipation in six European countries / J. Tack, V. Stanghellini, F. Mearin [et al.] //
BMC Gastroenterol. – 2019. – Vol.19, N 1. – P. 69.
88. Efficacy and safety of 5‒hydroxytryptamine 3 receptor antagonists in
irritable bowel syndrome: A systematic review and meta‒analysis of randomized
controlled trials / Y. Zheng, T. Yu, Y. Tang [et al.] // PLoS One. – 2017. – Vol. 12, N 3.
– P. e0172846. DOI: 10.1371/journal.pone.0172846.
89. Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel
Syndrome: A Meta‒Analysis / C. Xie, Y. Tang, Y. Wang [et al.] // PLoS One. – 2015. –
Vol. 10, N 8. DOI: 10.1371/journal.pone.0127815
https://t.me/med1917
123
90. Efficacy of antidepressants and psychological therapies in irritable bowel
syndrome: systematic review and meta‒analysis / A. C Ford, N. J. Talley, P. S.
Schoenfeld [et al.] // Gut. – 2009. – Vol. 58, N 3. – P. 367‒78.
91. Efficiency and safety of Enterosgel (polymethylsiloxane polyhydrate) in
the treatment of irritable bowel syndrome / E. I. Tkachenko, E. B. Avalueva, E. V.
Skazyvaeva [et al.] // Minerva Gastroenterologica e Dietologica. – 2015. – Vol. 61.,
Suppl. 1. – N. 2. P. 1-5.
92. Endocrine cells in the ileum of patients with irritable bowel syndrome / M.
Salhy, O. H. Gilja, D. Gundersen [et al.] // World J Gastroenterol. – 2014. Vol. 20, N9.
– P. 2383‒2391.
93. Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory
Neural Pathways / N. W. Bellono, J. R. Bayrer, D. B. Leitch [et al.] // Cell. – 2017. –
Vol. 170, N 1. – P 185–198.
94. Enteroendocrine cells: a review of their role in brain‒gut communication /
R. Latorre, C. Sternini, R. De Giorgio, B. Greenwood‒Van Meerveld
// Neurogastroenterol Motil. – 2016. – Vol. 28, N5. – P. 620‒630.
95. Estrogen rapidly modulates 5‒hydroxytrytophan‒induced visceral
hypersensitivity via GPR30 in rats / C. L. Lu, J. C. Hsieh, N. J. Dun [et al.] //
Gastroenterology. – 2009. – Vol. 137. – P. 1040‒1050.
96. Evidence for Local and Systemic Immune Activation in Functional
Dyspepsia and the Irritable Bowel Syndrome: A Systematic Review / G. Burns, G.
Carroll, A. Mathe [et al.] // Am J Gastroenterol. – 2019. – Vol. 114(3) . – P. 429-436.
97. Farré, R. Abnormal Barrier Function in Gastrointestinal Disorders / R.
Farré, M. Vicario // Handb Exp Pharmacol. – 2017. – Vol. 239. – P.193–217.
98. Ford, A. C. Mucosal inflammation as a potential etiological factor in
irritable bowel syndrome: a systematic review/ A. C. Ford, N. J. Talley // Journal of
gastroenterology. – 2011. – Vol. 46, N 4. – P. 421–431.
99. Ford, A. C. Characteristics of functional bowel disorder patients: a cross-
sectional survey using the Rome III criteria / A. C. Ford, P. Bercik, D. G. Morgan [et
al.] // Aliment. Pharmacol. Ther. – 2014. – Vol. 39. – P. 312–321.
https://t.me/med1917
124
100. Forsythe, P. Mast Cells in Neuroimmune Interactions / P. Forsythe //
Trends Neurosci. – 2019. – Vol. 42, N 1. – P. 43‒55.
101. Fukudo, S. On the organ choice in psychosomatic disorders. Irritable bowel
syndrome: a disorder of abnormal brain‒gut interactions / S. Fukudo, M. Hongo //
Japanese Journal of Psychosomatic Medicine. – 1999. – Vol. 39. – P. 159–166.
102. Gershon, M. D. 5‒Hydroxytryptamine (serotonin) in the gastrointestinal
tract / M. D. Gershon // Curr Opin Endocrinol Diabetes Obes. – 2013. – Vol. 20, N 1. –
P. 14‒21.
103. Global cytokine profiles and association with clinical characteristics in
patients with irritable bowel syndrome / S. M. Bennet, A. Polster, H. Tornblom [et al.] //
Am J Gastroenterol. – 2016. – Vol. 111, N 8. – P. 1165–1176.
104. Grundmann, O. Complementary and alternative medicines in irritable
bowel syndrome: An integrative view / O. Grundmann, S. L. Yoon // World Journal of
Gastroenterology. – 2014. – Vol. 20. – P. 346–362.
105. Gwee, K. A. Irritable bowel syndrome in developing countries: a disorder
of civilization or colonization / K. A. Gwee // Neurogastroenterol Motil. – 2005. – Vol.
17, N 3. – P. 317–324.
106. Hagsäter, S. M. 5‒HT6 receptor antagonism reduces defecation in rat: A
potential treatment strategy for irritable bowel syndrome with diarrhea / S. M. Hagsäter,
A. Lisinski, E. Eriksson // European Journal of Pharmacology. – 2019. – Vol.
864:172718. DOI: 10.1016/j.ejphar.2019.172718.
107. Herr, N. The Effects of Serotonin in Immune Cells / N. Herr, C. Bode, D.
Duerschmied // Front Cardiovasc Med. – 2017. – Vol. 4, N 48. DOI:
10.3389/fcvm.2017.00048.
108. High efficacy of bismuth subcitrate for Helicobacter pylori eradication in
pangastritis / C. Severi, M. Abdullahi, R. Tari [et al.] // Dig Liver Dis. – 2009. – Vol.
41, N 8. – P. 555-558.
109. How Serotonin Level Fluctuation Affects the Effectiveness of Treatment in
Irritable Bowel Syndrome / I. S. Vahora, N. Tsouklidis, R. Kumar [et al.] // Cureus. –
2020. – Vol. 12, N9. – DOI: 10.7759/cureus.9871.
https://t.me/med1917
125
110. Immune activation in patients with irritable bowel syndrome / T. Liebregts,
B. Adam, C. Bredack [et al.] // Gastroenterology. – 2007. – Vol. 132, N 3. – P. 913-920.
111. Impact of serotonin transporter gene polymorphism on brain activation by
colorectal distention / S. Fukudo, M. Kanazawa, T. Mizuno [et al.] // Neuroimage. –
2009. – Vol. 47, N 3. – P. 946–951.
112. Impaired uptake of serotonin by platelets from patients with irritable bowel
syndrome correlates with duodenal immune activation / S. Foley, K. Garsed, G. Singh
[et al.] // Gastroenterology. – 2011. – Vol. 140, N 5. – P. 1434‒1443.
113. Increased Colonic Epithelial Permeability and Mucosal Eosinophilia in
Ulcerative Colitis in Remission Compared With Irritable Bowel Syndrome and Health /
G. Katinios, M. Casado‒Bedmar, S. A. Walter [et al.] // Inflamm Bowel Dis. – 2020. –
Vol. 26, N 7. – P. 974‒984.
114. Increased immunoendocrine cells in intestinal mucosa of postinfectious
irritable bowel syndrome patients 3 years after acute Shigella infection‒‒an observation
in a small case control study / H. S. Kim, J. H. Lim, H. Park, S. I. Lee // Yonsei Med J.
– 2010. – Vol. 51, N 1. – P. 45‒51.
115. Inflammatory cell distribution in colon mucosa as a new tool for diagnosis
of irritable bowel syndrome: A promising pilot study / J. Boyer, M. C. Saint‒Paul, B.
Dadone [et al.] // Neurogastroenterol Motil. – 2018. – Vol. 30, N 1. DOI:
10.1111/nmo.13223.
116. Inflammatory cytokines and oxidative stress biomarkers in irritable bowel
syndrome: association with digestive symptoms and quality of life / R. Choghakhori, A.
Abbasnezhad, A. Hasanvand, R. Amani // Cytokine. – 2017. – Vol. 93. – P. 34–43.
117. International Union of Basic and Clinical Pharmacology. CX.
Classification of Receptors for 5‒hydroxytryptamine / N. M. Barnes, G. P. Ahern, P. C.
Becamel [et al.] // Pharmacology and Function Pharmacological Reviews. – 2021. –
Vol. 73, N 1. – P. 310‒520.
118. Intestinal epithelial barrier and neuromuscular compartment in health and
disease / V. D'Antongiovanni, C. Pellegrini, M. Fornai [et al.] // World J Gastroenterol.
– 2020. – Vol. 26, N 14. – P. 1564‒1579.
https://t.me/med1917
126
119. Intestinal epithelial responses to enteric pathogens: effects on the tight
junction barrier, ion transport, and inflammation / J. Berkes, V. K. Viswanathan, S. D.
Savkovic, G. Hecht // Gut. – 2003. –Vol. 52, N 3. – P. 439‒451.
120. Intestinal permeability ‒ a new target for disease prevention and therapy /
S. C. Bischoff, G. Barbara, W. Buurman [et al.] // BMC Gastroenterol. – 2014. – Vol.
14:189. DOI: 10.1186 / s12876-014-0189-7
121. Intestinal serotonin release, sensory neuron activation, and abdominal pain
in irritable bowel syndrome / C. Cremon, G. Carini, B. Wang [et al.] //Am J
Gastroenterol. – 2011. – Vol. 106, N 7. – P. 1290‒1298.
122. Irritable bowel syndrome: a clinical rewiew / W.D. Chey, J. Kurlander, S.
Eswaran [et al.] // JAMA. – 2015. – Vol. 313, N 9. – P. 949‒958.
123. Johnson, C. M. Fibromyalgia and Irritable Bowel Syndrome in Female
Pelvic Pain / C. M. Johnson, G. E. H. Makai // Semin Reprod Med. – 2018. – Vol. 36, N
2. – P. 136‒142.
124. Keita, A. V. Mucosal permeability and mast cells as targets for functional
gastrointestinaldisorders / A. V. Keita, J. D. Söderholm // Curr Opin Pharmacol. – 2018.
– Vol. 43. – P. 66–71.
125. Kellow, J. E. Altered small bowel motility in irritable bowel syndrome is
correlated with symptoms / J. E. Kellow, S. F. Phillips // Gastroenterology. – 1987. –
Vol. 92, N 6. – P. 1885‒1893.
126. Kim, D. Y. Serotonin: a mediator of the brain‒gut connection / D. Y. Kim,
M. Camilleri // The American Journal of Gastroenterology. – 2000. – Vol. 95, N 10. –
P. 2698–2709.
127. Kim, Y. S. Sex‒Gender Differences in Irritable Bowel Syndrome / Y. S.
Kim, N. Kim // J Neurogastroenterol Motil. – 2018. – Vol. 24, N 4. – P. 544‒558.
128. Kułak‒Bejda, A. Antidepressants for irritable bowel syndrome‒A
systematic review / A. Kułak‒Bejda, G. Bejda, N. Waszkiewicz // Pharmacol Rep. –
2017. – Vol. 69, N 6. – P. 1366‒1379.
https://t.me/med1917
127
129. Lazaridis, N. Current insights into the innate immune system dysfunction
in irritable bowel syndrome / N. Lazaridis, G. Germanidis // Ann. Gastroenterol. – 2018.
– Vol. 31, N 2. – P. 171–187.
130. Lee, O. Y. Asian motility studies in irritable bowel syndrome / O. Y. Lee
// J. Neurogastroenterol. Motil. – 2010. ‒ Vol. 16, N 2. – P. 120–130.
131. León‒Ponte, M. Serotonin provides an accessory signal to enhance T‒cell
activation by signaling through the 5‒HT7 receptor / M. León‒Ponte, G. P. Ahern, P. J.
O'Connell // Blood. –2007. – Vol. 109, N 8. – P. 3139‒3146.
132. Lewis, S. J. Stool form scale as a useful guide to intestinal transit time / S.
J. Lewis, K. W. Heaton // Scand J Gastroenterol. – 1997. – Vol. 32, N 9. – P. 920‒924.
133. Liddle, R. A. Neuropods / R. A. Liddle // Cell Mol Gastroenterol Hepatol.
– 2019. – Vol. 7, N4. – P. 739‒747.
134. Lind, C. D. Motility disorders in the irritable bowel syndrome / C. D. Lind
// Gastroenterol Clin North Am. – 1991. – Vol. 20, N 2. – P. 279‒295.
135. Long‒term efficacy and safety of ramosetron in the treatment of diarrhea‒
predominant irritable bowel syndrome / T. Chiba, K. Yamamoto, S. Sato [et al.] // Clin
Exp Gastroenterol. – 2013. – Vol. 6. – P. 123‒128.
136. Loss‒of‒function of the voltage‒gated sodium channel NaV1.5
(channelopathies) in patients with irritable bowel syndrome / A. Beyder, A. Mazzone, P.
R. Strege [et al.] // Gastroenterol. – 2014. – Vol. 146, N 7. – P. 1659–1668.
137. Lovell, R. M. Effect of gender on prevalence of irritable bowel syndrome
in the community: systematic review and meta‒analysis / R. M. Lovell, A. C. Ford //
Am J Gastroenterol. – 2012. – Vol. 107, N 7. – P. 991–1000.
138. Lovell, R. M. Global prevalence of and risk factors for irritable bowel
syndrome: A meta-analysis / R. M. Lovell, A. C. Ford // Clin Gastroenterol Hepatol. –
2012. – Vol. 10, N 7. – P. 712–21.
139. Makker, J. Genetic epidemiology of irritable bowel syndrome / J. Makker,
S. Chilimuri, J. N. Bella // World J Gastroenterol. – 2015. – Vol. 21, N 40. – P. 11353‒
11361.
https://t.me/med1917
128
140. Martin-Viñas, J. J. Immune response in irritable bowel syndrome: A
systematic review of systemic and mucosal inflammatory mediators / J. J. Martin-Viñas,
E. M. Quigley // J Dig Dis. – 2016. – Vol. 17, N 9. – P. 572-581.
141. Mast cell degranulation mediates bronchoconstriction via serotonin and not
via renin release / M. Krop, Z. G. Ozunal, W. Chai [et al.] // Eur J Pharmacol. – 2010. –
Vol. 640, N 1-3. – P. 185–189.
142. Mast cells are increased in the small intestinal mucosa of patients with
irritable bowel syndrome: A systematic review and meta‒analysis / A. Robles, D. Perez
Ingles, K. Myneedu [et al.] // Neurogastroenterol Motil. – 2019. – Vol. 31, N 12. – DOI:
10.1111 / Nmo.13718.
143. Maternal serotonin transporter genotype affects risk for ASD with exposure
to prenatal stress / P. M. Hecht, M. Hudson, S. L. Connors [et al.] // Autism Res. –
2016. – Vol. 9, N 11. – P. 1151‒1160.
144. Mawe, G. M. Serotonin signalling in the gut‒‒functions, dysfunctions and
therapeutic targets / G. M. Mawe, J. M. Hoffman // Nat Rev Gastroenterol Hepatol. –
2013. – Vol. 10, N 8. – P. 473‒486.
145. Mayer, E. A. Brain‒gut microbiome interactions and functional bowel
disorders / E. A. Mayer, T. Savidge, R. J. Shulman // Gastroenterology. – 2014. – Vol.
146, N 6. – P. 1500–1512.
146. Mechanism of gastroprotection by bismuth subsalicylate against chemically
induced oxidative stress in cultured human gastric mucosal cells / D. Bagchi, T. R.
McGinn, X. Ye [et al.] // Digestive Diseases and Sciences. – 1999. – Vol. 44. – P.
2419–2428.
147. Mechanisms of stress‒induced visceral pain: implications in irritable bowel
syndrome / B. Greenwood‒Van Meerveld, R. D. Moloney, A. C. Johnson [et al.] //
J Neuroendocrinol. – 2016. – Vol. 28, N 8. DOI: 10.1111/jne.12361.
148. Meleine, M. Gender‒related differences in irritable bowel syndrome:
Potential mechanisms of sex hormones / M. Meleine, J. Matricon // World J
Gastroenterol. – 2014. – Vol. 20, N 22. – P. 6725‒6743.
https://t.me/med1917
129
149. Microbiota‒gut‒brain axis and its affect inflammatory bowel disease:
Pathophysiological concepts and insights for clinicians / E. Sinagra, E. Utzeri, G. C.
Morreale [et al.] // World J Clin Cases. – 2020. – Vol. 8, N 6. – P. 1013‒1025.
150. Molecular and cellular mechanisms of tight junction dysfunction in the
irritable bowel syndrome / P. Cheng, J. Yao, C. Wang [et al.] // Molecular Medicine
Reports. – 2015. – Vol. 12, N 3. – P. 3257–3264.
151. Motility response to colonic distention is increased in postinfectious
irritable bowel syndrome (PI‒IBS) / M. Kanazawa, O. S. Palsson, M. A. van Tilburg [et
al.] // Neurogastroenterol Motil. – 2014. – Vol. 26, N 5. – P. 696‒704.
152. Mucosal immune activation in irritable bowel syndrome: gender‒
dependence and association with digestive symptoms / C. Cremon, L. Gargano, A. M.
Morselli‒Labate [et al.] //Am J Gastroenterol. ‒ 2009. ‒ Vol. 104. ‒ № 2. ‒P. 392‒400.
153. Mulak, A. Sex difference in irritable bowel syndrome: do gonadal
hormones play a role / A. Mulak, Y. Taché // Gastroenterol Pol. ‒ 2010. ‒ Vol. 17, N 2.
‒ P. 89–97.
154. Neuroanatomy of lower gastrointestinal pain disorders / W. Vermeulen, J.
G. De Man, P. A. Pelckmans, B. Y. De Winter // World J Gastroenterol. – 2014. – Vol.
20, N. 4. – P. 1005-1020.
155. New technologies to investigate the brain‒gut axis / A. Sharma, D. Lelic,
C. Brock [et al.] // World J. Gastroenterol. – 2009. – Vol. 15. N 2. – P. 182–191.
156. New therapeutic perspectives in irritable bowel syndrome: Targeting low‒
grade inflammation, immuno‒neuroendocrine axis, motility, secretion and beyond / E.
Sinagra, G. C. Morreale, G. Mohammadian [et al.] // World J Gastroenterol. – 2017. –
Vol. 23, N 36. – P. 6593‒6627.
157. Nichols, D. E. Psychedelics / D. E. Nichols // Pharmacol Rev. – 2016. –
Vol. 68, N 2. – P. 264‒355.
158. O’Malley, D. Altered expression and secretion of colonic interleukin‒6 in a
stress‒sensitive animal model of brain‒gut axis dysfunction / D. O’Malley, T. G. Dinan,
J. F. Cryan // J Neuroimmunol. – 2011. – Vol. 235, N 1‒2. – P. 48–55.
https://t.me/med1917
130
159. Overlap between irritable bowel syndrome and common gastrointestinal
diagnoses: a retrospective cohort study of 29,553 outpatients in Germany / S.H. Loosen,
K. Kostev, Jördens MS [et al.] // BMC Gastroenterol. – 2022. – Vol. 22(1), 48.
doi: 10.1186/s12876-022-02118-y
160. Overlap of functional heartburn and gastroesophageal reflux disease with
irritable bowel syndrome / N. Bortoli., I. Martinucci, M. Bellini [et al.] // World J
Gastroenterol. – 2013. – Vol. 19. – N 35. – Р. 5787–5797.
161. Overlapping gastroesophageal reflux disease and irritable bowel syndrome:
increased dysfunctional symptoms / S. S. Yarandi, S. Nasseri-Moghaddam, P.
Mostajabi [et al.] // World J. Gastroenterol. – 2010. – Vol. 16. – P. 1232–1238.
162. Pain hypersensitivity in patients with functional gastrointestinal disorders:
a gastrointestinal specific defect or a general systemic condition / M. Bouin, P. Meunier,
M. Riberdy‒Poitras, P. Poitras // Dig Dis Sci. – 2001. – Vol. 46, N 11. – P. 2542–2548.
163. Pathophysiology underlying irritable bowel syndrome – from the viewpoint
of dysfunction of autonomic nervous system activity / N. Manabe, T. Tanaka, J. Hata [et
al.] // J Smooth Muscle Res. – 2009. – N 45. – P. 15–23.
164. Piche, T. Tight junctions and IBS‒‒the link between epithelial
permeability, low‒grade inflammation, and symptom generation? / T. Piche //
Neurogastroenterol Motil. – 2014. – Vol. 26, N 3. – P. 296‒302.
165. Postinfectious irritable bowel syndrome after a food-borne outbreak of
acute gastroenteritis attributed to a viral pathogen / J.K. Marshall, M. Thabane, M.R.
Borgaonkar [et al] // Clin Gastroenterol Hepatol. – 2007. – N 5 – P. 457-460.
166. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After
Infectious Enteritis: A Systematic Review and Meta‒analysis / F. Klem, A. Wadhwa, L.
J. Prokop [et al.] // Gastroenterology. – 2017. – Vol. 152, N 5. – P. 1042‒1054.
167. Psychosocial aspects of the functional gastrointestinal disorders / D. A.
Drossman, F. H. Creed, G. A. Fava [et al.] // Gastroenterol. Int. – 1995. – Vol.8, N 2. –
P. 47–90.
168. Rectal bismuth subsalicylate as therapy for ulcerative colitis / S. D. Ryder,
R. J. Walker, H. Jones [et al.] // Aliment PharmacolTher. – 1990. – № 4. – Р. 333–338.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана